Our year-end list captures the 10 that sparked heaviest interest.
The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
Subscribers will be able to use co-pay cards on Obamacare exchanges.
The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.
Bruce Lehman, one of the longest-serving CEOs in the medical agency world, will retire at year's end, agency officials confirmed, spurring new leadership at the firm he co-founded in 1978, LehmanMillet.
Novo redoubled its Victoza marketing efforts after a recent setback, and that's made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.
GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.
The Wizards of White Oak are spending $10 million on DTC ad research. Is this a wise use of sparse agency resources?
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
Marci Piasecki was promoted to regional director, North America, with oversight over all five US professional agencies in McCann Health, the most senior of a series of personnel moves the network said are designed to bolster the operation.
Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.
BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
Gwee, who pioneered pharma social media at Vertex before moving onto the agency side, is tasked with integrating digital and social strategies across the marketing and PR network's 14 agencies.
Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.
Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.
Otsuka-Lundbeck CNS alliance extended to Alzheimer's drug; longtime DAS chief Tom Harrison steps down to chairman emeritus role
What will become of Dollars for Docs after the Sunshine provisions go into effect? We asked Charles Ornstein, who told us what's next for the project.
Industry observances of Rare Disease Awareness Day are getting more elaborate of late—perhaps not solely for altruistic reasons, as a third of NMEs approved by FDA over the past five years were for the treatment of rare diseases.
Dorothy Gemmell, who headed sales and sales operations at the portal, will take the reins at Havas Life New York.
Sobi and Savient Pharmaceuticals inked a co-promote agreement for RA drug Kineret in the US.
GSK says 2013 will be a springboard for future growth, Burson-Marsteller hands out two new executive titles.
Novo Nordisk promoted a quartet of US execs to SVP and announced sales growth of 18% for 2012.
Healthcare PR giant Dan Edelman dies; Pfizer says 'no comment' on breakup speculation; Publicis Healthcare snags a new SVP; Lippincott gives nurses a new drug diagnosis tool.
Biogen pulls ALS treatment from its pipeline, Merck resubmits cholesterol combo to FDA
AstraZeneca's 7,300 layoffs were not the last word for 2012, Alcon gets hit with an untitled letter from OPDP, and Novo creates an all-diabetic sports team
The company's first-ever road show has stimulated sales for its new ClinicalKey reference tool, grabbing the attention of time-harried doctors for as long as 30 minutes during the workday.
A third-party review says FDA employees need more support; Shire launches rare disease research; and Bayer drops Schiff bid
Teva kicks off a succession plan early, and Merck launches Phase II trials of two all-oral hepatitis C regimens.
Boston Scientific's new CEO takes office, Watson creates a generics management team
WebMD named Global Crossing alum John Kritzmacher SVP of business operations, while Wolters Kluwer named a new president and CEO of medical research.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.